Complete patient enrollment in the GATHER2 Phase 3 trial of Zimura
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company is accelerating the timeline for when it expects to complete enrollment in GATHER2 to the third quarter of 2021.”
What we found
Evidence strength A What the grades mean
Filings consistently state that GATHER2 patient enrollment was completed in July 2021, before the stated third-quarter 2021 deadline.
-
A IVERIC bio, Inc. 10-Q filed 2021-11-09
“In July 2021, the Company completed patient enrollment for GATHER2, its Phase 3 clinical trial evaluating the safety and efficacy of Zimura for the treatment of GA secondary to AMD.” ✓ confirmed on the page
-
A IVERIC bio, Inc. 10-K filed 2022-02-24
“In July 2021, the Company completed patient enrollment for GATHER2, its Phase 3 clinical trial evaluating the safety and efficacy of Zimura for the treatment of GA secondary to AMD.” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Completion of GATHER2 Phase 3 patient enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you IVERIC bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C410939-025065 · Corrections policy